Mutational Impact Heligenics offers a cutting-edge GigaAssay platform that functionally maps all potential amino acid substitutions, enabling cancer diagnostics firms and pharma companies to interpret mutations with greater accuracy and accelerate targeted therapy development.

Biologic Drug Edge As the first to apply High Content Screening to biologics, Heligenics provides a differentiator for drug development programs focused on biologic drugs, presenting a compelling sales angle to biotech and pharma teams pursuing precision medicine approaches.

Functional Data Value The rich functional data generated by Heligenics can improve genetic test interpretation for diagnostics companies and assist in redesigning trials for genetically stratified cohorts, offering cross-sell opportunities across diagnostics and clinical research services.

Growth Readiness With a recent $4.5M financing and a revenue range of $1M–$10M, Heligenics is a nimble growth-stage partner likely open to collaborations, pilots, and early-stage partnerships to validate value in oncology, genetic testing, and personalized medicine workflows.

Tech & Partnerships Leveraging a modern tech stack (cloud, AI, and scalable web tools) alongside global outreach channels (LinkedIn, website, email), Heligenics is positioned to engage enterprise biotech and pharma clients through targeted outreach and co-development opportunities.